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Abstract: Biodegradable galactosylated methoxy poly(ethylene glycol)/poly(l-lactide-co-
β-malic acid) (Gal-PEG-b-PLMA) block copolymer micelles were successfully prepared by a 
solvent diffusion method, and could efficiently encapsulate doxorubicin. The Gal-PEG-b-PLMA 
micelles before and after doxorubicin loading were characterized by size,   morphology, in 
vitro drug release, and in vitro cytotoxicity in HepG2 cells. Transmission electron   microscopy 
and dynamic light scattering results showed that the empty and doxorubicin-loaded micelles 
were approximately spherical in shape and had mean sizes of about 72 nm and 85 nm, 
  respectively. In vitro release behavior of doxorubicin from the micelles was pH-dependent, 
with   obviously faster release rates at mildly acidic pH 4.5 and 5.5 compared with physiologic 
pH 7.4.   Methylthiazoletetrazolium assay and flow cytometric analysis indicated that the 
  doxorubicin-loaded galactosylated micelles exhibited a greater growth-inhibitory effect on 
HepG2 cells than the nongalactosylated doxorubicin-loaded micelles, and induced S phase cell 
cycle arrest.   Confocal laser scanning microscope observations revealed that the galactosylated 
micelles could be efficiently internalized by HepG2 cells through receptor-mediated endocytosis. 
The results suggest that Gal-PEG-b-PLMA copolymer micelles are a promising carrier system 
for targeted drug delivery in cancer therapy.
Keywords: polymer micelles, targeted drug delivery, doxorubicin, chemotherapy, hepatocel-
lular carcinoma
Introduction
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death 
throughout the world,1 and is strongly associated with highly prevalent hepatitis B virus 
infections and exposure to food contaminated with aflatoxin B1. In China alone, the 
estimated annual incidence of new HCC cases is more than 350,000 (approximately 
55% of global HCC cases),2 and HCC is the second most common cause of cancer-
related death. Surgical resection is considered the optimal treatment approach, but 
is very limited in HCC patients because of high rates of recurrence and metastasis 
after surgery. Moreover, conventional chemotherapy is associated with toxicity to 
normal tissues. In addition, HCC is well known to be highly resistant to chemotherapy 
drugs.3 Therefore, it is of great importance to search for more effective systemic 
  chemotherapeutic options to improve the survival rate of HCC patients.4 Amongst 
these, the rapid development of targeted drug delivery systems holds great promise 
for the treatment of HCC.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Doxorubicin, a well known anticancer drug, has shown 
strong antitumor activity against various solid tumors, includ-
ing those of the breast, bladder, lung, ovary, and liver.5 How-
ever, its clinical therapeutic potential is restricted by both low 
bioavailability and serious systemic toxic side effects to nor-
mal tissues. To address these problems, a great deal of effort 
has been focused on developing novel drug delivery systems, 
including liposomes, micelles, dendrimers, hyperbranched 
polymers, microspheres, and hydrogels.6–8 During this time, 
nanosized polymeric delivery systems have attracted consid-
erable attention, because they not only control drug-release 
kinetics but also preferentially accumulate in solid tumors 
via passive targeting based on an enhanced permeability and 
retention effect. Amongst the biodegradable and nontoxic 
polymers used to prepare nanocarriers, amphiphilic block 
copolymers have been extensively explored and are rapidly 
advancing. They can self-assemble into spherical micelles 
exhibiting a core-shell architecture composed of hydrophobic 
segments as their inner core and hydrophilic segments as their 
outer shell in aqueous media.9 The core serves as a nanodepot 
for hydrophobic anticancer drugs,10 and is protected by the 
hydrophilic shell.
However, more and more observations show that no 
substantial therapeutic improvement can be sufficiently 
guaranteed by passive targeting.11 As we know, the sites of 
action of many chemotherapeutic agents are located in cells, 
and the efficient intracellular uptake of drugs by cancer cells 
is regarded as the determining step for antitumor activity. 
Therefore, many researchers have aimed to develop more 
effective site-specific delivery strategies by incorporating 
targeting ligands or antibodies into the surfaces of drug 
carriers, permitting them to be taken up by active receptor-
mediated endocytosis.12–14 This can significantly improve the 
therapeutic effect of anticancer drugs and minimize toxic 
side effects to normal tissues.15 In active targeted therapy 
for HCC, galactose is considered to be a promising ligand 
because it can specifically recognize and bind asialoglyco-
protein receptor, which is overexpressed exclusively on the 
surfaces of hepatic parenchymal cells.16,17 Galactose has been 
conjugated to drug carriers to achieve targeted chemothera-
peutic or diagnostic agent delivery to HepG2 cells overex-
pressing the asialoglycoprotein receptor, although the precise 
mechanism of asialoglycoprotein receptor-mediated uptake 
of galactose-modified carriers into HepG2 cells remains   
unresolved.
The most prominent synthetic polyesters, such as polylac-
tide, poly(lactic-co-glycolic acid), poly(ε-caprolactone), and 
their derivatives, have been extensively used in biomedical 
fields of controlled drug delivery, suture lines, and tissue 
engineering18 because they are nontoxic, biocompatible, 
and bioabsorbable in vivo. However, when used as drug 
carriers, the high crystallinity of polylactide would lead to 
a slow degradation rate, resulting in retarded drug release. 
Therefore, polylactide is usually copolymerized with func-
tional monomers or grafted onto natural polymers to obtain 
ideal copolymers. Recently, some biodegradable polymers 
with pendant functional groups, such as hydroxyl, carboxyl, 
amine, and carboxylate, are attracting more interest because 
they may be used to conjugate drug molecules via functional 
covalent bonds and electrostatic actions, endowing the carri-
ers with stimuli-responsive properties. In the past few years, 
poly(lactic acid-co-malic acid) (PLMA), a biocompatible and 
biodegradable copolyester with pendent carboxyl groups, 
has attracted some attention in biomedical applications.19–21 
In this study, PLMA was evaluated as a potential antitumor 
drug carrier. We prepared targeting polymeric micelles from 
amphiphilic PEG-b-PLMA copolymer and investigated the 
feasibility of galactosylated PEG-b-PLMA (Gal-PEG-b-
PLMA) micelles as an active targeting carrier for the targeted 
delivery of doxorubicin to HepG2 cells. The doxorubicin-
loaded polymer micelles were characterized in terms of size 
and morphology, drug loading, in vitro drug-release behavior, 
and in vitro cell cytotoxicity.
Materials and methods
Materials
The HepG2 cell line used in this study was obtained from the 
Cell Institute of Academia Sinica (Shanghai, China). Doxo-
rubicin was supplied by Beijing Huafeng United Technology 
Co. Ltd. (Beijing, China). Fetal bovine serum and bovine calf 
serum were purchased from Hangzhou Sijiqing Biological 
Engineering Materials Co., Ltd. (Hangzhou, China). 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT), 1-ethyl-3,3-dimethylaminopropyl carbodiimide 
hydrochloride (EDC), triethylamine, poly(ethylene gly-
col) bis(amine) (NH2-  PEG-NH2, molecular weight 2000), 
and methoxy poly(ethylene glycol) (molecular weight 
2000) were obtained from Sigma Co. (Shanghai, China). 
N-hydroxysuccinimide (NHS) was obtained from Sinopharm 
Chemical Reagent Co. (Shanghai, China). Dulbecco’s Modi-
fied Eagle’s Medium,   RPMI-1640 medium, trypsin-EDTA 
(0.5% trypsin, 5.3 mM EDTA), and the antibiotic agents pen-
icillin-streptomycin (100 U/mL) were purchased from Gibco 
BRL (Gaithersburg, MD). The dialysis membrane (molecular 
weight cutoff 3500 Da) was purchased from Beijing Solar-
bio Science and Technology Co., Ltd. (Beijing, China). International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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The block copolymers were synthesized in our laboratory. 
All other chemicals were commercial products of analytic 
reagent grade, and were used as received unless otherwise   
stated.
Synthesis of Peg-b-PLMA and gal-Peg-
b-PLMA copolymers
Poly(l-lactide-co-β-benzyloxycarbonyl-β-propiolactone) 
(PLBCP), with a nominal molar ratio of about 85:15, and 
its block copolymer with methoxy-poly(ethylene glycol), ie, 
PEG-b-PLBCP, were synthesized as previously reported in 
the literature22,23 with some changes. Briefly, predetermined 
amounts of l-lactide (LA) and β-benzyloxycarbonyl-β-
propiolactone (BCP) or their mixture with MPEG were placed 
in a polymerization tube (8 mL), and 0.5 mL of dried toluene 
solution containing the catalyst Sn(Oct)2 (0.1% w/w) was 
added into the tube. The tube was evacuated by a vacuum 
pump at 30°C for 3 hours and then sealed. The ring-  opening 
copolymerization was performed at 140°C for 24 hours. After 
polymerization, the reaction system was cooled to ambient 
temperature, and the product was dissolved in CH2Cl2, pre-
cipitated twice with cold diethyl ether, and dried at 35°C for 
36 hours in a vacuum oven. Galactosylated PEG-b-PLBCP 
(Gal-PEG-b-PLBCP) was further synthesized by conjugating 
PLBCP with Gal-PEG-NH2 at room temperature for 48 hours 
via the carbodiimide method. Gal-PEG-NH2 was obtained 
from galactose and NH2-PEG-NH2 through the condensa-
tion reaction between NH2-PEG-NH2 and galactonic acid 
in the presence of NHS/EDC. Before entrapping drug or 
preparing micelles, PEG-b-PLBCP and Gal-PEG-b-PLBCP 
were transformed, respectively, into PEG-b-PLMA and Gal-
PEG-b-PLMA by removing the protecting benzyl groups 
of BCP units by introducing H2 in the presence of a Pd/C   
catalyst.
Preparation of polymer micelles  
and drug loading
Empty and doxorubicin-loaded polymer micelles were 
prepared by a solvent diffusion method. Briefly, 50 mg of 
PEG-b-PLMA or its mixture with Gal-PEG-b-PLMA (molar 
ratio of 25:1) dissolved in 2 mL of CH2Cl2, with or without 
addition of 1–15 mg of doxorubicin dissolved in 0.25 mL 
of dimethyl sulfoxide, was added dropwise into 10 mL of 
aqueous solution in a round-bottom flask under magnetic 
stirring at room temperature. The mixture was sonicated 
for 30 minutes to form a homogeneous micelle solution. 
Gentle stirring was continued under reduced pressure until 
the organic solvent had evaporated completely. The micelles 
were recovered by centrifugation at 12,000 × g and washed 
3 times with deionized water. Dry nanomicelles were also 
collected by freeze drying.
To determine drug loading content and encapsulation 
efficiency, doxorubicin-loaded micelles were separated by 
centrifugation at 12,000 × g, and the exact doxorubicin 
concentration in the solutions was determined by ultraviolet-
visible spectrometry (Ultraviolet-visible   Spectrophotometer, 
Puxi Scientific Instruments, Beijing, China) by monitoring 
the characteristic absorbance of doxorubicin at 480 nm 
using a calibration curve. The calibration curve of the 
ultraviolet-visible absorbency was generated with a known 
doxorubicin concentration range of 0.01–45 µg/mL. Drug 
loading content was expressed as the percentage of drug 
amount loaded into micelles with respect to the total 
amount of drug-loaded micelles. Encapsulation efficiency 
was defined as the percentage of the drug amount incorpo-
rated into micelles with respect to the initially added drug 
amount to the formulation. All samples were analyzed in   
triplicate.
Micelle characterization
The morphology of the prepared copolymeric micelles was 
characterized by transmission electron microscopy (TEM, 
JEM-200CX, Jeol Co., Japan). A drop of diluted micellar 
solution (0.1 mg/mL) was placed on a copper TEM grid, and 
observed at an accelerating voltage of 80 kV . The micelle 
size and size distribution were measured by dynamic light 
scattering using a Zetasizer Nano-ZS size analyzer (Malvern 
Instruments Ltd., Malvern, UK). Measurements were carried 
out in double-distilled H2O at 25°C and at a fixed wavelength 
of 633 nm.
The critical micelle concentration of the block polymers 
was determined by the pyrene method.24 The concentration of 
polymer solutions was varied from 0.02 µg/mL to 0.2 mg/mL, 
and the final concentration of fluorescence probe pyrene was 
fixed at 0.2 µg/mL. The fluorescence spectra were recorded 
using an LS55 spectrometer (Perkin-Elmer, Waltham, MA) 
with an excitation wavelength of 350 nm. Emission fluo-
rescence at 372 and 383 nm was monitored. Dynamic light 
scattering and critical micelle concentration measurements 
were done in triplicate for each sample, and the results were 
taken as the average of three measurements.
In vitro release of doxorubicin  
from polymer micelles
In vitro release behavior of doxorubicin from PEG-b-
PLMA micelles (about 8% drug-loaded samples) was International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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observed for 72 hours in phosphate-buffered saline at 
different pH (4.5, 5.5, and 7.4) using a dialysis-diffusion 
method. Briefly, doxorubicin-loaded micelles were diluted 
with corresponding phosphate-buffered saline to give the 
desired concentration (2 mg/mL, 0.5 mL) and sealed in a 
dialysis bag, and the dialysis bag was immersed in 10 mL 
of the release buffer in a 15 mL capped centrifuge tube. 
The centrifuge tubes were placed in an incubator shaker 
with gentle shaking at 37°C. At predetermined time inter-
vals, 1 mL of release buffer was withdrawn from the tube 
and replaced with the same amount of fresh buffer. The 
amount of doxorubicin released in the collected buffer 
samples was determined by ultraviolet-visible spectro-
photometric analysis. The release experiments were con-
ducted in triplicate, and the results presented are average   
data.
In vitro cell cytotoxicity
For all the cell culture studies, HepG2 cells were used as a 
model tumor cell line and maintained in RPMI1640 medium 
with 10% fetal bovine serum, 0.1% nonessential amino 
acids, and 100 U/mL penicillin-streptomycin at 37°C in a 
humidified atmosphere containing 5% CO2. The in vitro 
anticancer effect (cytotoxicity) of the drug-loaded micelles 
was   evaluated using the MTT assay. Briefly, HepG2 cells 
at logarithmic growth phase were separately seeded in 
96-well plates at a seeding density of 1 × 104 cells/well and 
incubated for 24 hours to allow the cells to attach, followed 
by washing with ice-cold phosphate-buffered saline three 
times and replacing with fresh medium. Thereafter, the cells 
were treated with free doxorubicin, doxorubicin-loaded 
PEG-b-PLMA micelles, and Gal-PEG-b-PLMA micelles. 
The equivalent concentration of doxorubicin in the three 
formulations was set at 0.05–40 µg/mL. After the prede-
termined incubation time, 20 µL MTT solution (5 mg/mL 
in phosphate-buffered saline) was added to each well, and 
four hours later each well was replaced with dimethyl sul-
foxide to ensure solubilization of formazan crystals. Cell 
viability was quantified by measuring absorbance at 570 nm 
on a microplate reader (EL310, Bio-Tek Instruments Inc., 
Winooski, VT), calculated and expressed as a percentage 
of the absorbance in control cells compared with that in the 
treated cells.
Intracellular uptake of doxorubicin
To observe the intracellular doxorubicin distribution in 
micelles, the HepG2 cells were seeded in Lab-Tek® eight-
well chambers (Nalgene, Nunc Inc., Denmark) at a density 
of 5.0 × 104 cells/well and cultured overnight, followed 
by coincubation with the three doxorubicin formulations 
(equivalent doxorubicin concentration 5 µg/mL) for 
12 hours. The treated cells were washed three times with 
ice-cold phosphate-buffered saline (pH 7.4), fixed with 
4% paraformaldehyde in 95% ethanol at −20°C overnight, 
and examined by a confocal laser scanning microscope at 
excitation and emission wavelengths of 490 and 560 nm, 
respectively. The HepG2 cells were washed once again with 
phosphate-buffered saline before flow cytometry analysis 
(FACScan flow cytometry, BD Biosciences, Franklin Lakes, 
NJ). The experiments were performed in triplicate and 
the data were analyzed using the FAC station software   
program.
Statistical analysis
Results were expressed as mean ± standard deviation based 
on three independent measurements. Statistical analyses were 
performed by one-way analysis of variance to determine differ-
ences among the measured properties of each group using a sta-
tistical program (SPSS 10; SPSS Inc, Chicago, IL). Statistical 
significance was defined as a probability level of P , 0.05 in all   
cases.
Results and discussion
Synthesis of gal-Peg-b-PLMA copolymer
The schematic synthesis procedure for Gal-PEG-b-PLMA 
copolymers is shown in Figure 1. The ring-opening copoly-
merization of two cyclic aliphatic lactone monomers, LA and 
BCP, could proceed smoothly in the absence or presence of 
MPEG-OH at 140°C using Sn(Oct)2 as a catalyst, and the 
removal of protecting benzyl groups in BCP units yielded 
the corresponding PLMA or PEG-b-PLMA copolymer. Their 
physical properties are summarized in Table 1. The molecular 
weight of PLMA was Mn 11.5 kDa, with a polydispersity of 
1.32. Gal-PEG-b-PLMA was further synthesized from Gal-
PEG-NH2 and PLMA in anhydrous dimethyl sulfoxide via 
the condensation reaction between the amino groups of Gal-
PEG-NH2 and the carboxylic groups of PLMA in the pres-
ence of NHS/EDC. When the copolymerization of LA and 
BCP was performed in the presence of PEG, the feed molar 
ratio of PEG to the two monomers was set at 1.39:85:15. 
The final copolymer had a PEG/LA/BCP molar ratio of 
1.4:86:14, which was close to the ratio in feed, whereas, 
in the absence of PEG, the LA/BCP molar ratio of PLMA 
copolymer was 87:13, and also approximated the feed molar 
ratio of 85:15. These findings indicate that these two cyclic 
ester monomers are capable of copolymerizing in the absence International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1033
copolymer micelles for targeted drug delivery
CH3
CH3
CH2
OCH2C6H5
CH
CH
HC
O
O O
O
O
O
O C
C
C
C
M-PEG2000-OH
Sn(Oct)2, 140°C, 24h
(i) Sn(Oct)2, 140°C, 24h
(ii) Gal-PEG2000-NH2,EDC/NHS
H3CO
Gal
PEG2000
PEG2000
O
O
O O
O
O
O
O
O
O
O
C
C
CH2
CH2
CH3
CH3
HC
HC
CH
CH
COOCH2C6H5
COOCH2C6H5
x
x
y
y
C
H3CO
Pd/C, H2
Gal
PEG2000
PEG2000
O
NH
O
O
O
O
O
O
C
C
CH2
CH2
CH3
CH3
HC
HC
CH
CH
COOH
COOH
x
x
y
y
C
C
C NH
Gal-PEG-b-PLMA
Gal-PEG-b-PLBCP
PEG-b-PLBCP
PEG-b-PLMA
+
Figure 1 Synthesis scheme of Peg-b-PLMA and gal-Peg-b-PLMA copolymers.
Abbreviations: Peg-b-PLMA, methoxy poly(ethylene glycol)/poly(l-lactide-co-β-malic acid) block copolymer; gal-Peg-b-PLMA, galactosylated methoxy poly(ethylene 
glycol)/poly(l-lactide-co-β-malic acid) block copolymer.
Table 1 Physical properties of PLMA and Peg-b-PLMA copolymers
Molar ratio in feed 
(PEG/LA/BCP)
Molar ratio in copolymer 
(PEG/LA/MA)
Yield (%) Mn (1H NMR) Polydispersity
PLMA 0:85:15 0:87:13 92 11500 1.32
Peg-b-PLMA 1.39:85:15 1.4:86:14 95 13000 1.16
Abbreviations: PLMA, poly(l-lactide-co-β-malic acid); Peg-b-PLMA, methoxy poly(ethylene glycol)/poly(l-lactide-co-β-malic acid) block copolymer.
or presence of PEG to produce PLMA and PEG-b-PLMA   
copolymers.
Preparation and characterization  
of polymer micelles
In general, the micellization of amphiphilic block   copolymers 
in a selective solvent of one of the blocks is a typical   feature 
of their colloidal properties. In the present study, when 
amphiphilic PEG-b-PLMA copolymer was dissolved in 
an aqueous solution that was a thermodynamically good 
solvent for PEG block and a precipitant for PLMA block, 
the copolymer chains could associate reversibly to form 
micellar aggregates, in which the hydrophobic PLMA cores 
were surrounded by hydrophilic PEG shells. Therefore, 
the hydrophobic doxorubicin could be incorporated into 
micelles through the partitioning of doxorubicin within the International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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cores of PEG-b-PLMA micelles formed by self-assembly 
of the copolymer.
The size and morphology of empty and doxorubicin-
loaded PEG-b-PLMA micelles were investigated by dynamic 
light scattering and TEM. Figure 2 shows the typical 
size distribution profiles and mean sizes of empty and   
doxorubicin-loaded PEG-b-PLMA micelles. As shown in 
Figure 2, empty and doxorubicin-loaded micelles exhibit nar-
row unimodal size distributions, and the corresponding mean 
sizes are about 71.9 ± 8.4 nm and 84.5 ± 11.4 nm, respec-
tively. The dynamic light scattering result indicates that the 
entrapped doxorubicin molecules in the hydrophobic PLMA 
inner cores increased the mean size of the micelles. The TEM 
images of empty and drug-loaded PEG-b-PLMA micelles (as 
shown in Figure 3) indicate that the micelles had approxi-
mately spherical morphology and a smooth surface without 
any aggregation, and the average sizes of the micelles before 
and after doxorubicin loading were about 61 nm and 70 nm, 
respectively, which were smaller than those determined by 
dynamic light scattering. The most probable reason for this is 
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Figure 2 Size distributions of (A) empty, (B) doxorubicin-loaded gal-Peg-b-PLMA 
micelles, and (C) their mean sizes measured by dynamic light scattering method.
Abbreviation:  gal-Peg-b-PLMA,  galactosylated  methoxy  poly(ethylene  glycol)/
poly(l-lactide-co-β-malic acid) block copolymer.
Figure 3 Transmission electron microscopic images of (A) empty and (B) doxorubicin 
loaded gal-Peg-b-PLMA micelles.
Abbreviation:  gal-Peg-b-PLMA,  galactosylated  methoxy  poly  (ethylene  glycol)/
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the shrinkage of the PEG shell caused by the evaporation of 
water during drying before TEM observations. As we know, 
the particle size and surface characteristics of micelles have 
a significant impact on the in vivo fate of a micelle drug 
delivery system. Generally, micelles of ,100 nm diameter 
with hydrophilic surfaces have a longer circulation time in 
blood and can selectively accumulate at tumor sites as a 
result of an enhanced permeability and retention effect25 or be 
preferentially taken up by tumor cells via receptor-mediated 
endocytosis,26 because they readily escape from monocytes 
and the reticuloendothelial system.
Doxorubicin has demonstrated significant activity in 
clinical applications against a wide variety of tumors. 
  However, its serious side effects in normal tissues restrict its 
wide application. Therefore, the incorporation of doxorubi-
cin into the cores of PEG-b-PLMA micelles would not only 
increase solubility of the drug but also reduce side effects. 
During the experiments, the amount of doxorubicin incorpo-
rated into the polymer micelles increased as the initial feed 
weight ratio of doxorubicin to copolymer increased. The drug 
loading content and encapsulation efficiency of doxorubicin 
in PEG-PLMA micelles could vary from 2.58% ± 0.44% 
and 28.1% to 16.4% ± 0.58% and 92.5%, respectively, by 
adjusting the feed drug-to-polymer weight ratio. The reason 
for the high drug-loading capacity is that doxorubicin could 
be encapsulated into the PEG-b-PLMA micelles through 
the cooperative hydrophobic and electrostatic (hydrogen 
bond) interactions between the PLMA block with pendant 
carboxylic groups and doxorubicin with an amine group. 
However, when the feed weight ratio of doxorubicin to 
polymer was higher than 0.16:1, little aggregation was found, 
and drug-loading efficiency gradually decreased due to the 
hydrophobic nature of doxorubicin. Thus, the initial feed 
weight ratio of doxorubicin to polymer was fixed at 0.11:1 for 
all samples, and the actual drug loading content and encap-
sulation efficiency were 7.93% ± 0.56% and 83.2% ± 3.7%, 
respectively. In addition, the critical micelle concentration 
values of PEG-b-PLMA and Gal-PEG-b-PLMA were as low 
as 0.9 and 1.1 µg/mL, respectively. The results suggested that 
the micelles had high stability and would have the ability 
to maintain their integrity even with strong dilution in the   
body.
In vitro release profile of doxorubicin 
from micelles
Characterization of the in vitro release of doxorubicin from 
PEG-b-PLMA micelles is important to assess the stabil-
ity of doxorubicin incorporated into the micelle. The in 
vitro release behavior of doxorubicin from PEG-b-PLMA 
micelles was investigated by the dialysis method at 37°C 
and at pH 4.5, 5.5, and 7.4, as shown in Figure 4. The results 
demonstrate that the micelles exhibited pH-dependent 
release behavior, whereby much faster release of doxorubicin 
took place at an acidic pH 4.5 and 5.5 than at physiologic 
pH 7.4. For instance, at least 30, 20, and 10% of the initial 
doxorubicin amount was released within 5 hours at pH 4.5, 
5.5, and 7.4, respectively, while within 48 hours, about 
78%, 67%, and 31% of doxorubicin was released at pH 4.5, 
5.5, and 7.4, respectively. It should be noted that over 65% 
of the doxorubicin was released at a lower pH of 4.5 after 
24 hours. These results suggest that rapid drug release at 
endosomal pH renders the pH-responsive micelles promis-
ing as smart nanovehicles for triggered release of lipophilic 
anticancer drugs. The in vitro release profile depicted in 
Figure 4 indicates two-phase release behavior, ie, a burst 
release during the initial several hours, followed by a slow 
sustained-release phase, which can be described by the zero-
order equation and Higuchi’s equation,   respectively. A burst 
release of 15%–45% doxorubicin occurred in the first 
10 hours, and is attributed to those drug molecules existing 
near the micellar surface and on the interface of the micelle 
hydrophobic core and hydrophilic shell, which easily diffuse 
within the first few hours of incubation via both passive 
diffusion and hydration, whereas the drug incorporated 
into the inner core compartment inside the micelles would 
be responsible for sustained release after the first 10 hours. 
The results indicated that release of drug from the micelles 
was diffusion-controlled.
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The mechanism of pH-responsive doxorubicin release 
might involve protonation of the amine group of doxorubicin 
and the ionization degree of the carboxylic groups in the 
PLMA block (pKa value of PLMA copolymer 3.81). Under 
physiologic conditions, the hydrophobic and electrostatic 
interactions between PLMA and doxorubicin were relatively 
strong, and could prevent rapid drug release. However, under 
mildly acidic conditions, the protonation degree of   doxorubicin 
increases, and the ionization degree of the carboxyl groups 
in PLMA decreases, which leads to weaker interaction 
between doxorubicin and PLMA. At the same time, repulsion 
between protonated doxorubicin molecules might facilitate 
  doxorubicin to diffuse out of the micelles. In addition, the car-
boxylic acid groups could catalyze the hydrolysis degradation 
of PLMA at low pH values, namely, PLMA erosion. The above 
three mechanisms could lead to rapid in vitro release.
In vitro cytotoxicity in hepg2 cells
The cytotoxic mechanism of doxorubicin involves   induction of 
DNA damage, inhibition of cell proliferation, cell cycle status, 
and cell death.27 To determine the biologic effects of doxo-
rubicin in HepG2 cells, the cytotoxicity of serial   equivalent 
concentrations of doxorubicin in the three different formula-
tions (free doxorubicin, doxorubicin-loaded PEG-b-PLMA 
micelles, and doxorubicin-loaded Gal-PEG-b-PLMA micelles) 
to HepG2 cells was investigated by MTT assay after 24 hours 
of incubation, as shown in Figure 5. Empty PEG-b-PLMA 
micelles were used as a negative control. HepG2 cells were 
reported to overexpress asialoglycoprotein receptors on their 
surface and to be sensitive to doxorubicin.28,29 Figure 5 shows 
clearly that the viability of HepG2 cells gradually decreased 
with increasing doxorubicin concentration. Significant dif-
ferences in cell cytotoxicity were observed among the three 
formulations at high doxorubicin doses (.0.5 µg/mL).
In the case of PEG-b-PLMA micelles without galactose 
groups, the viability of HepG2 cells was as high as 73.2% 
when the concentration of doxorubicin was 1 µg/mL. In con-
trast, galactosylated micelles exhibited significantly superior 
cytotoxicity against HepG2 cells, and the cell survival rate was 
65.4%. The cells treated with the doxorubicin-loaded Gal-PEG-
b-PLMA micelles exhibited lower survival rates than those 
treated with doxorubicin-loaded PEG-b-PLMA micelles. This 
result implies that galactosylated micelles could be effectively 
transferred into HepG2 cells via galactose receptor-mediated 
endocytosis, producing more efficient killing of cancer cells.
Apoptosis of HepG2 cells induced by the three formula-
tions was also observed by flow cytometry. The respective 
doxorubicin concentration was adjusted to 5 µg/mL, and 
the cells were treated with the test solutions for 12 hours. 
Figure 6 shows the cell cycle profiles of HepG2 cells before 
and after the doxorubicin treatments. As shown in Figure 6, 
significant S phase cell cycle arrest is observed in all three 
doxorubicin treatment groups. The percentages of cells in the 
S phase are 39.3% ± 1.84% for the free doxorubicin group, 
53.2% ± 3.1% for the doxorubicin-loaded PEG-b-PLMA 
micelle group, and 47.6% ± 2.1% for the doxorubicin-
loaded Gal-PEG-b-PLMA micelle group, respectively, and 
are much higher than the 27.2% ± 0.86% recorded for the 
control group. This result is accompanied by lower percent-
ages of G0/G1 phase cells and higher percentages of G2/M 
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phase cells in the three doxorubicin-treated groups. It is 
also noted that the percentages of S phase cells in the two 
doxorubicin-loaded micelle groups are higher than those 
in the free doxorubicin group. However, no obvious cell 
cycle changes were found among the three doxorubicin 
formulations. Therefore, doxorubicin released from micelles 
can restore the cell cycle in HepG2 cells, ie, blocking cells 
at the S phase and retarding G2/M phase progression.
Targeting activity of gal-Peg-b-PLMA 
micelles in hepg2 cells
The intracellular delivery of doxorubicin into tumor cells is 
essential to its antitumor activity, because its site of action 
is at the double-stranded helix DNA in cell nuclei.11 There-
fore, to endow a drug carrier with active targeting ability, 
a bioactive ligand must be available on the carrier surface 
for efficient chemical ligation of the ligand and its receptor. 
The cellular uptake of the three doxorubicin formulations 
in HepG2 cells was evaluated by confocal laser scanning 
microscopy, and the representative images of HepG2 cells are 
shown in Figure 7. All three doxorubicin formulations had an 
equivalent doxorubicin concentration of 5 µg/mL. It can be 
seen from Figure 7 that fluorescent doxorubicin was visual-
ized in HepG2 cells treated with the three doxorubicin for-
mulations. However, the detected fluorescence in cells treated 
with doxorubicin-loaded PEG-b-PLMA micelles was much 
weaker than that in the cells treated with doxorubicin-loaded 
targeted micelles, indicating that doxorubicin-loaded Gal-
PEG-b-PLMA micelles were more efficiently internalized by 
HepG2 cells. The result confirmed that galactose-modified 
micelles could be selectively uptaken by HepG2 cells via 
asialoglycoprotein receptor-mediated endocytosis.
Conclusion
New amphiphilic PEG-PLMA block copolymer micelles were 
successfully developed for targeted delivery of poorly soluble 
doxorubicin to HepG2 cells. The polymer micelles, composed 
of a PEG block as the hydrophilic shell and a PLMA block 
with pendant carboxylic groups as the hydrophobic core, could 
effectively incorporate doxorubicin through the combination 
of hydrophobic and electrostatic interactions between doxo-
rubicin and PLMA. The critical micelle concentration value, 
drug loading content, and encapsulation efficiency of doxoru-
bicin in the PEG-PLMA micelles were about 1 µg/mL, 8wt%, 
and 83%, respectively. The doxorubicin-loaded or -  nonloaded 
micelles exhibited a smooth surface and spherical shape, and 
had an average size of less than 100 nm. The micelles showed 
pH-responsive release behavior, ie, doxorubicin release at 
mildly acidic pH 4.5 and pH 5.5 was much faster than that 
at physiologic pH 7.4. The pH-responsive release behavior 
is closely related to the presence of carboxyl groups in the 
PLMA block.   Gal-PEG-b-PLMA micelles could be selec-
tively taken up by HepG2 cells through asialoglycoprotein 
  receptor-  mediated   endocytosis, and exhibited much higher 
Figure 7 confocal laser scanning microscopic images of hepg2 cells (5 × 104 cells/mL) 
after 12 hours of in vitro exposure to (A) free doxorubicin, (B) doxorubicin-loaded 
Peg-b-PLMA micelles, and (C) doxorubicin-loaded gal-Peg-b-PLMA micelles.
Abbreviations: Peg-b-PLMA, methoxy poly(ethylene glycol)/poly (l-lactide-co-β-
malic acid); gal-Peg-b-PLMA, galactosylated methoxy poly(ethylene glycol)/poly(l-
lactide-co-β-malic acid).International Journal of Nanomedicine
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cytotoxicity than   ungalactosylated micelles. The doxoru-
bicin-loaded micelles could   produce S cell cycle arrest in 
HepG2 cells. Therefore, the pH-responsive   PEG-b-PLMA 
micelles are   promising   nanovehicles for targeted delivery of 
poorly soluble anticancer drugs.
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